Hence, targeting EpCAM+++ ovarian tumor cells and/or the associated STAT3 pathway in combination with chemotherapy may help achieve durable clinical responses in recurrent ovarian cancer patients. This evidence concerns the gene STAT3 and ovarian cancer.